GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
GENMAB A/S
Financials through fiscal 2025, year ended Dec 31, 2025
$38.50+1.50 (+4.05%)
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 3, 2023 | During market hours | $4.20B | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 10, 2022 | During market hours | – | – | – |
Press releases
Announcements Genmab A/S filed with the SEC
Grant of Restricted Stock Units and Warrants to Employees in Genmab
EX-99.1 to Form 6-K
Capital Increase in Genmab as a Result of Employee Warrant Exercise
EX-99.1 to Form 6-K
Notice to Convene an Extraordinary General Meeting of Genmab A/S
EX-99.1 to Form 6-K
To the Shareholders of Genmab A/S
EX-99.2 to Form 6-K
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
Capital Increase in Genmab as a Result of Employee Warrant Exercise
EX-99.1 to Form 6-K
Capital Increase in Genmab as a Result of Employee Warrant Exercise
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
Grant of Restricted Stock Units and Warrants to Employees in Genmab
EX-99.1 to Form 6-K
Capital Increase in Genmab as a Result of Employee Warrant Exercise
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
Genmab Announces Financial Results for the First Quarter of 2026
EX-99.1 to Form 6-K
Genmab A/S Share Capital Reduction
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
Passing of Genmab A/S’ Annual General Meeting
EX-99.1 to Form 6-K
Completion of Share Buy-back Program
EX-99.1 to Form 6-K
Transactions in Connection with Share Buy-back Program
EX-99.1 to Form 6-K
Correction to Company Announcement No. 13 of March 2, 2026
EX-99.1 to Form 6-K
Transactions in Connection with Share Buy-back Program
EX-99.1 to Form 6-K
Capital Increase in Genmab as a Result of Employee Warrant Exercise
EX-99.1 to Form 6-K
Transactions in Connection with Share Buy-back Program
EX-99.1 to Form 6-K